Immunotherapy with autologous dendritic cells and tumor-specific synthetic peptides for synovial sarcoma

J Pediatr Hematol Oncol. 2002 Mar-Apr;24(3):220-3. doi: 10.1097/00043426-200203000-00012.

Abstract

Synovial sarcoma in an 11-year-old Japanese girl relapsed 5 months after autologous stem cell transplantation. Autologous dendritic cells (DCs) were generated from her peripheral blood mononuclear cells using granulocyte/macrophage colony-stimulating factor and IL-4. Dendritic cells were pulsed with synthetic peptides containing a junctional region of SYT-SSX2 fusion protein generated by t(X;18) and were administered once per week. No side effects were observed. Growth of metastatic nodules in the lung was temporally suppressed. The delayed-type hypersensitivity responses in skin were enhanced to tumor lysate but not to peripheral blood mononuclear cell lysate. The CD3+ cells cultured with pulsed DCs lysed tumor cells in vitro. Immunotherapy using DCs and tumor-specific peptides may be a safe approach in the treatment of childhood cancer.

Publication types

  • Case Reports
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antigens, Neoplasm / immunology
  • Bone Neoplasms / therapy*
  • Cells, Cultured / cytology
  • Cells, Cultured / immunology
  • Child
  • Cytotoxicity, Immunologic / immunology
  • DNA Primers / chemistry
  • Dendritic Cells / immunology*
  • Female
  • Humans
  • Immunotherapy*
  • Interleukin-4 / immunology
  • Neoplasm Proteins / therapeutic use*
  • Neoplasm Recurrence, Local / therapy*
  • Oncogene Proteins, Fusion / therapeutic use*
  • Peptides / chemical synthesis
  • Peptides / immunology*
  • Radiography, Thoracic
  • Sarcoma, Synovial / therapy*
  • T-Lymphocytes, Cytotoxic / immunology
  • Thoracic Neoplasms / therapy*

Substances

  • Antigens, Neoplasm
  • DNA Primers
  • Neoplasm Proteins
  • Oncogene Proteins, Fusion
  • Peptides
  • SYT-SSX fusion protein
  • Interleukin-4